Kim Baker
- Sustained efficacy from 3 to 6 months following bronchoscopic thermal vapor ablation (BTVA) in the treatment of heterogeneous emphysemaBy Felix Herth, Gregory Snell, Peter Hopkins, Kim Baker, Christian Witt, Mark H. Gotfried, Arshang Valipour, Manfred Wagner, Franz Stanzel, Jim Egan, Steven Kesten and Armin ErnstFelix Herth1Pneumology and Critical Care Medicine, Thoraxklinik Heidelberg, Heidelberg, GermanyGregory Snell2Allergy Immunology & Respiratory Medicine, The Alfred Hospital, Melbourne, AustraliaPeter Hopkins3Lung Transplant Unit, Prince Charles Hospital, Chermside, AustraliaKim Baker4Pulmonary and Critical Care Medicine, University of Iowa, Iowa City, United StatesChristian Witt5Pneumology, Charité Campus-Mitte, Berlin, GermanyMark H. Gotfried6Pulmonary Associates, John C. Lincoln Hospital, Phoenix, United StatesArshang Valipour7Ludwig-Boltzmann-Institute for COPD, Otto-Wagner-Hospital, Vienna, AustriaManfred Wagner8Pneumologie, Klinikum Nürnberg, Nürnberg, GermanyFranz Stanzel9Pneumologie, Zentrum für Pneumologie, Hemer, GermanyJim Egan10Advanced Lung Disease Program, Mater Misericordiae University Hospital, Dublin, IrelandSteven Kesten11Clinical Department, Uptake Medical Corp, Tustin, United StatesArmin Ernst12Pulmonary Critical Care and Sleep Medicine, Caritas St. Elizabeth's Medical Center, Boston, United States
- High resolution computed tomography (HRCT) measurements of lobar volume reduction associated with bronchoscopic thermal vapor ablation (BTVA) in patients with heterogeneous emphysemaBy Arschang Valipour, Felix J.F. Herth, Gregory Snell, Peter Hopkins, Kim Baker, Christian Witt, Mark H. Gotfried, Manfred Wagner, Franz Stanzel, Jim Egan, Steven Kesten and Armin ErnstArschang Valipour1Ludwig-Boltzmann-Institute for COPD, Otto-Wagner-Hospital, Vienna, AustriaFelix J.F. Herth2Pneumology and Critical Care Medicine, Thoraxklinik Heidelberg, Heidelberg, GermanyGregory Snell3Allergy Immunology & Respiratory Medicine, The Alfred Hospital, Melbourne, AustraliaPeter Hopkins4Lung Transplant Unit, Prince Charles Hospital, Chermside, AustraliaKim Baker5Pulmonary & Critical Care Medicine, University of Iowa, Iowa City, United StatesChristian Witt6Pneumology, Charité Campus-Mitte, Berlin, GermanyMark H. Gotfried7Pulmonary Associates, John C. Lincoln Hospital, Phoenix, United StatesManfred Wagner8Pneumologie, Klinikum Nürnberg, Nürnberg, GermanyFranz Stanzel9Pneumologie, Zentrum für Pneumologie, Hemer, GermanyJim Egan10Advanced Lung Disease Program, Mater Misericordiae University Hospital, Dublin, IrelandSteven Kesten11Clinical Department, Uptake Medical Corp., Tustin, United StatesArmin Ernst12Pulmonary, Critical Care and Sleep Medicine, Caritas St. Elizabeth's Medical Center, Boston, United States
- Associations of efficacy outcomes following bronchoscopic thermal vapor ablation (BTVA) for the treatment of heterogeneous emphysemaBy Peter Hopkins, Felix J.F. Herth, Gregory Snell, Kim Baker, Christian Witt, Mark H. Gotfried, Arschang Valipour, Manfred Wagner, Franz Stanzel, Jim Egan, Steven Kesten and Armin ErnstPeter Hopkins1Lung Transplant Unit, Prince Charles Hospital, Chermside, AustraliaFelix J.F. Herth2Pneumology and Critical Care Medicine, Thoraxklinik Heidelberg, Heidelberg, GermanyGregory Snell3Allergy Immunology & Respiratory Medicine, The Alfred Hospital, Melbourne, AustraliaKim Baker4Pulmonary and Critical Care Medicine, University of Iowa, Iowa City, IA, United StatesChristian Witt5Pneumology, Charité Campus-Mitte, Berlin, GermanyMark H. Gotfried6Pulmonary Associates, John C. Lincoln Hospital, Phoenix, AZ, United StatesArschang Valipour7Ludwig-Boltzmann-Institute for COPD, Otto-Wagner-Hospital, Vienna, AustriaManfred Wagner8Pneumology, Klinikum Nürnberg, Nürnberg, GermanyFranz Stanzel9Pneumologie, Zentrum für Pneumologie, Hemer, GermanyJim Egan10Advanced Lung Disease Program, Mater Misericordiae University Hospital, Dublin, IrelandSteven Kesten11Clinical Department, Uptake Medical Corp, Tustin, CA, United StatesArmin Ernst12Pulmonary Critical Care and Sleep Medicine, Caritas Ct. Elizabeth's Medical Center, Boston, MA, United States
- Associations among one-year efficacy outcomes following endoscopic thermal vapor ablation (InterVapor™) for heterogeneous emphysemaBy Peter Hopkins, Felix J.F. Herth, Gregory Snell, Kim Baker, Christian Witt, Mark H. Gotfried, Arschang Valipour, Manfred Wagner, Franz Stanzel, Jim J. Egan, Steven Kesten and Armin ErnstPeter Hopkins1Lung Transplant Unit, Prince Charles Hospital, Chermside, AustraliaFelix J.F. Herth2Pneumology and Critical Care Medicine, Thoraxklinik Heidelberg, GermanyGregory Snell3Allergy Immunology & Respiratory Medicine, The Alfred Hospital, Melbourne, AustraliaKim Baker4Pulmonary & Critical Care Medicine, University of Iowa, Iowa City, United StatesChristian Witt5Pneumology, Charité-University Medicine, Berlin, GermanyMark H. Gotfried6PACT, Pulmonary Associates, Phoenix, United StatesArschang Valipour7Ludwig-Boltzmann-Institute for COPD and Respiratory Epidemiology, Otto-Wagner Hospital, Vienna, AustriaManfred Wagner8Pneumologie, Klinikum Nürnberg, GermanyFranz Stanzel9Zentrum für Pneumologie, Lungenklinik Hemer, Nordrhein Westfalen, GermanyJim J. Egan10Advanced Lung Disease Program, Mater Misericordiae University Hospital, Dublin, IrelandSteven Kesten11Clinical Department, Uptake Medical Corp, Tustin, United StatesArmin Ernst12Pulmonary, Critical Care and Sleep Medicine, St. Elizabeth's Medical Center, Boston, United States
- The influence of emphysema heterogeneity on the magnitude of benefit following endoscopic thermal vapor ablation (InterVapor™) in patients with heterogeneous emphysemaBy Felix J.F. Herth, Armin Ernst, Peter Hopkins, Jim J. Egan, Franz Stanzel, Arschang Valipour, Manfred Wagner, Christian Witt, Kim Baker, Mark H. Gotfried, Steven Kesten and Gregory SnellFelix J.F. Herth1Pneumology and Critical Care Medicine, Thoraxklinik Heidelberg, GermanyArmin Ernst2Pulmonary, Critical Care and Sleep Medicine, St. Elizabeth's Medical Center, Boston, United StatesPeter Hopkins3Lung Transplant Unit, Prince Charles Hospital, Chermside, AustraliaJim J. Egan4Advanced Lung Disease Program, Mater Misericordiae University Hospital, Chermside, AustraliaFranz Stanzel5Zentrum für Pneumologie, Lungenklinik Hemer, Nordrhein Westfalen, GermanyArschang Valipour6Ludwig-Boltzmann Institute for COPD and Respiratory Epidemiology, Otto-Wagner Hospital, Vienna, AustriaManfred Wagner7Pneumologie, Klinikum Nürnberg, GermanyChristian Witt8Pneumology, Charité University Medicine, Berlin, GermanyKim Baker9Pulmonary and Critical Care Medicine, University of Iowa, Iowa City, United StatesMark H. Gotfried10PACT, Pulmonary Associates, Phoenix, United StatesSteven Kesten11Allergy Immunology & Respiratory Medicine, The Alfred Hospital, Melbourne, AustraliaGregory Snell11Allergy Immunology & Respiratory Medicine, The Alfred Hospital, Melbourne, Australia
- The influence of baseline exercise tolerance on long-term efficacy outcomes following endoscopic thermal vapor ablation (InterVapor™) in patients with heterogeneous emphysemaBy Arschang Valipour, Felix J.F. Herth, Armin Ernst, Peter Hopkins, Jim J. Egan, Franz Stanzel, Manfred Wagner, Christian Witt, Kim Baker, Mark H. Gotfried, Steven Kesten and Gregory SnellArschang Valipour1Ludwig-Boltzmann-Institute for COPD and Respiratory Epidemiology, Otto-Wagner Hospital, Vienna, AustriaFelix J.F. Herth2Pneumology and Critical Care Medicine, Thoraxklinik Heidelberg, GermanyArmin Ernst3Pulmonary, Critical Care and Sleep Medicine, St. Elizabeth's Medical Center, Boston, United StatesPeter Hopkins4Lung Transplant Unit, Prince Charles Hospital, Chermside, AustraliaJim J. Egan5Advanced Lung Disease Program, Mater Misericordiae University Hospital, Dublin, IrelandFranz Stanzel6Zentrum für Pneumologie, Lungenklinik Hemer, Nordrhein Westfalen, GermanyManfred Wagner7Pneumologie, Klinikum Nürnberg, GermanyChristian Witt8Pneumology, Charité University Medicine, Berlin, GermanyKim Baker9Pulmonary & Critical Care Medicine, University of Iowa, Iowa City, IA, United StatesMark H. Gotfried10PACT, Pulmonary Associates, Phoenix, United StatesSteven Kesten11Clinical Department, Uptake Medical Corp., Tustin, United StatesGregory Snell12Allergy Immunology & Respiratory Medicine, The Alfred Hospital, Melbourne, Australia
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.